Market News & Trends
BD Completes Clinical Trial for Wearable Injector
BD (Becton, Dickinson and Company), a leading global medical technology company, recently announced the completion of a 50-subject human clinical trial with the BD Libertas…
Zumutor Biologics & Catalent Collaborate to Manufacture First-in-Class mAb to Treat Solid Tumors
Catalent recently announced it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor…
BeyondSpring’s Plinabulin Stimulates Both the Adaptive & Innate Immune System
BeyondSpring Inc. recently announced that new clinical data on the company’s first-in-class, late-stage asset, Plinabulin, shows its ability to potently stimulate the innate immune system.…
Credence MedSystems Receives Award for Best Innovation in Drug Delivery Devices
Credence MedSystems, an innovator in injectable drug delivery technology for the biopharmaceutical industry, has received the Pharmapack Award for its….
Biologics Patent Expiry Trend Expected to Have Positive Impact
Expectations for biosimilars are high in 2020, and the drug class will finally begin to make its mark in the US, says GlobalData, a leading…
Stevanato Group & Bormioli Pharma Sign Collaboration Agreement
Stevanato Group, through Ompi, its specialist in glass primary packaging for the pharmaceutical industry, and Bormioli Pharma recently announced a collaboration agreement that will enable…
Synteract Expands Into Asia Pacific & South Africa Through Acquisition of Specialty Biometrics CRO
Synteract recently acquired Clindata’s human health biometrics division to meet market demand for more adaptable biometrics services solutions. This acquisition extends Synteract’s existing global footprint…
CURE Pharmaceutical Signs Exclusive Licensing Agreement With ReLeaf Europe
CURE Pharmaceutical recently announced it has signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products.…
AskBio Announces First Patient Dosed in Phase 1 Trial
Asklepios BioPharmaceutical (AskBio) and its NanoCor Therapeutics subsidiary recently announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101.…
Cellectricon & StressMarq Biosciences Collaborate to Develop Next-Generation Reagents & Assays
Cellectricon recently announced a collaboration with StressMarq Biosciences. As a supplier of life science reagents such as primary antibodies, antibody conjugates, proteins, immunoassay kits and…
PharmaCyte Biotech Will Have All the Protection It Needs Upon Marketing Approval
PharmaCyte Biotech recently announced it is about to embark upon a planned US FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic cancer (LAPC) at trial sites all over the US, and with that journey comes the….
Two Labs Acquires CEEK Enterprises
Two Labs recently announced it has acquired CEEK Enterprises, a management consultancy dedicated to supporting clients in the biopharma and MedTech industries with specialized expertise in….
Pelican BioThermal Announces the Acquisition of NanoCool
Pelican BioThermal recently announced the acquisition of NanoCool, an Albuquerque, New Mexico-based manufacturer of temperature-controlled packaging solutions. This acquisition further…..
Catalent to Acquire Leading Cell Therapy Company MaSTherCell Global
Catalent, Inc. recently announced it has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of…..
Conatus Pharmaceuticals & Histogen Enter Definitive Merger Agreement
Conatus Pharmaceuticals Inc. and Histogen Inc. recently announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly owned subsidiary of….
Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases
Albireo Pharma, Inc. recently announced a number of advances and new initiatives in the clinical program for odevixibat, an oral once daily capsule in development for….
BioPharmX & Timber Pharmaceuticals Announce Merger Agreement
BioPharmX Corporation and Timber Pharmaceuticals LLC recently announced they have entered into a definitive merger agreement. Under the terms of the merger agreement, subject to the approval of…..
Ubiquigent Launches a New Service to Facilitate Target Validation of DUB Enzymes & Determine Compound-DUB Target Engagement & Selectivity of Novel Compounds in Cells
Ubiquigent Limited (Ubiquigent) recently announced the launch of an exciting new service as part of its Drug Discovery Screening Platform – DUBprofiler-Cell. DUBprofiler-Cell supports the…
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134
Rubius Therapeutics, Inc. recently announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for…
Vetter Aligns its Development Service Laboratory Portfolio
Vetter, a global operating Contract Development and Manufacturing Organization (CDMO) has brought together its development laboratories in one Ravensburg site end of last year. Designed…